- Home
- CYCC vs BMEA Comparison
CYCC vs BMEA Comparison
Compare CYCC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- BMEA
- Stock Information
- Founded
- CYCC 1992
- BMEA 2017
- Country
- CYCC Malaysia
- BMEA United States
- Employees
- CYCC N/A
- BMEA N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- CYCC Health Care
- BMEA Health Care
- Exchange
- CYCC Nasdaq
- BMEA Nasdaq
- Market Cap
- CYCC 61.2M
- BMEA 65.8M
- IPO Year
- CYCC N/A
- BMEA 2021
- Fundamental
- Price
- CYCC $1.63
- BMEA $1.44
- Analyst Decision
- CYCC
- BMEA Strong Buy
- Analyst Count
- CYCC 0
- BMEA 11
- Target Price
- CYCC N/A
- BMEA $27.60
- AVG Volume (30 Days)
- CYCC 191.0K
- BMEA 703.1K
- Earning Date
- CYCC 05-15-2025
- BMEA 05-05-2025
- Dividend Yield
- CYCC 147.24%
- BMEA N/A
- EPS Growth
- CYCC N/A
- BMEA N/A
- EPS
- CYCC N/A
- BMEA N/A
- Revenue
- CYCC $14,000.00
- BMEA N/A
- Revenue This Year
- CYCC $137.21
- BMEA N/A
- Revenue Next Year
- CYCC N/A
- BMEA N/A
- P/E Ratio
- CYCC N/A
- BMEA N/A
- Revenue Growth
- CYCC N/A
- BMEA N/A
- 52 Week Low
- CYCC $1.36
- BMEA $1.29
- 52 Week High
- CYCC $49.34
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- CYCC 32.89
- BMEA 39.69
- Support Level
- CYCC $1.36
- BMEA $1.29
- Resistance Level
- CYCC $1.94
- BMEA $1.52
- Average True Range (ATR)
- CYCC 0.43
- BMEA 0.14
- MACD
- CYCC -0.07
- BMEA 0.01
- Stochastic Oscillator
- CYCC 8.31
- BMEA 28.17
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.